The effect of genetically engineered insulin on the metabolic and molecular mechanisms of regulation of behavior in rats with pancreatic pathology

The aim of the study was to determine reactivity in rats with alloxan diabetes and insulin therapy with genetically engineered insulin VINSUVET MIX ANIMALPEN 30/70 (BMA 30/70). The work showed that in Wistar rats with alloxan diabetes and BMA 30/70 insulin replacement therapy at a dose of 0.5 IU/kg of body weight, twice a day, the survival rate of animals significantly increases from 58.57 to 85.0%, body weight is restored, which confirms its effectiveness in correcting energy imbalance. Against the background of the use of the tested insulin, compensation of carbohydrate metabolism was recorded, as evidenced by stable blood glucose, lactate and fructosamine levels during the 90-day follow-up. The relationship between compensation of hyperglycemia and restoration of behavioral activity was established, the immunomodulatory effect of insulin BMA 30/70 was revealed, manifested by two-phase dynamics of the cytokine profile: activation of the antiinflammatory cytokine IL–4 was observed from the 14th to the 28th day of the experiment, and stabilization of the cytokine balance was observed from the 60th to the 90th day. A correlation between cytokine status and behavioral reactions has been proven, which confirms the involvement of inflammatory processes in the pathogenesis of diabetic complications.